Barclays PLC Has $118,000 Stake in CureVac (NASDAQ:CVAC)

Barclays PLC increased its position in shares of CureVac (NASDAQ:CVAC) by 51.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,836 shares of the company’s stock after purchasing an additional 11,890 shares during the period. Barclays PLC’s holdings in CureVac were worth $118,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in CVAC. Signaturefd LLC increased its holdings in shares of CureVac by 29.2% during the fourth quarter. Signaturefd LLC now owns 36,140 shares of the company’s stock worth $123,000 after buying an additional 8,170 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in CureVac by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company’s stock worth $162,000 after buying an additional 4,425 shares during the last quarter. Quadrant Capital Group LLC lifted its stake in shares of CureVac by 61.8% in the 4th quarter. Quadrant Capital Group LLC now owns 50,016 shares of the company’s stock valued at $171,000 after purchasing an additional 19,098 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of CureVac by 10.3% during the 4th quarter. Geode Capital Management LLC now owns 241,750 shares of the company’s stock worth $824,000 after buying an additional 22,491 shares during the period. Institutional investors own 17.26% of the company’s stock.

CureVac Trading Down 0.6%

Shares of CVAC stock opened at $3.37 on Thursday. The firm has a market cap of $756.02 million, a P/E ratio of 6.13 and a beta of 2.43. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. CureVac has a 12-month low of $2.37 and a 12-month high of $5.28. The business has a 50-day moving average price of $3.12 and a two-hundred day moving average price of $3.23.

CureVac (NASDAQ:CVAC) last posted its earnings results on Thursday, April 10th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). CureVac had a return on equity of 21.98% and a net margin of 20.72%. The company had revenue of $15.44 million during the quarter, compared to analysts’ expectations of $6.40 million. Equities analysts anticipate that CureVac will post 0.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on CVAC shares. JMP Securities reaffirmed a “market outperform” rating and issued a $16.00 price objective on shares of CureVac in a research note on Friday, February 14th. UBS Group decreased their price objective on shares of CureVac from $13.00 to $12.00 and set a “buy” rating for the company in a report on Wednesday, April 30th.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.